Abstract: Aspects of this disclosure relate generally to the use of biomaterials for the in vivo generation of CAR expressing cells. In some embodiments, the biomaterials comprise one or more of a cell recruitment composition, a viral vector, and/or a cell activation agent.

Abstract: The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods.

Abstract: The knot-tying tool is a device that is used to assist in tying knots. The knot-tying tool is adapted for use with monofilament line. The knot-tying tool is further adapted for use with fishing hooks. The knot-tying tool includes a hook holder and a knotting post. The hook holder holds a fishing hook or a swivel such that a fishing line can be threaded through the fishing hook or swivel. The knotting post is a shaft around which the fishing line can be looped so as to assist in tying the knot attaching the fishing line to the fishing hook or swivel. The knot-tying tool includes a handle, a hook holder, a sleeve, and a knotting post.

Abstract: The present disclosure provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for MST1R, which plays an integral role in various disorders or conditions, such as cancer. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the disclosure also can be used in the diagnostics field, as well as for further investigating the role of MST1R in the progression of disorders associated with tumors. The disclosure also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

Abstract: An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.

Abstract: Ginseng extracts as well as preparations such as medicaments, pharmaceuticals and food or dietary supplements for use to treat or prevent alopecia areata in subjects requiring such treatment or prevention are provided. The ginseng extract is a carbohydrate extract that contains between about 60-70 wt % carbohydrates, for example.

Abstract: An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.

Abstract: The invention is directed to a method of treating hematological malignancies by administering to the subject ginseng fractions from North American ginseng (Panax quinquefolium). The present invention can be used to activate the proliferation of hemopoietic cells in a patient in need of treatment, or as a therapeutic targeted at conditions characterized by hematological malignancy, such as an abnormal proliferation of blood cells, lymphocytes, multiple myeloma, etc. The invention also includes a method of treating leukemia by activating the proliferation of natural killer (NK) cells and monocytes in the bone marrow and the spleen of the patient by administering at least one ginseng fraction selected from the group consisting of CVT-E002, PQ.sub.2, PQ.sub.223 and purified fractions from CVT-E002, PQ.sub.2 and PQ.sub.223. The present invention may be used to treat the hematological malignancy or as a supplement for patients undergoing chemotherapy or radiation therapy.

Abstract: The invention is directed to ginseng fractions, methods of preventing or reducing hematological malignancies such as leukemia, and methods of elevating NK cells in a subject by administering to the subject an effective amount of a ginseng fraction, a pharmaceutical composition comprising the fraction in combination with another medicament or with one or more pharmaceutically acceptable carriers including food items. The fraction may be made from Panax quinquefolius or may be selected from CVT-E002, PQ2, PQ223 and purified fractions from CVT-E002, PQ2 and PQ223.

Abstract: Disclosed herein are methods for the recombinant expression of mammalian cell membrane-bound human CCN1 or a CCN1 domain thereof in mammalian cells, comprising transforming a mammalian host cell with a vector encoding CCN1 or a CCN1 domain thereof C-terminally fused to a mammalian cell transmembrane domain (CCN1 fusion protein), expressing said CCN1 or CCN1 domain fusion protein in said host cell, and recovering said membrane bound CCN1 or said CCN1 domain thereof. Disclosed herein is the use of such membrane bound CCN1 and domain for the generation of corresponding antibodies. Antibodies against human CCN1 are useful for the treatment of diseases.

Abstract: Disclosed herein are methods for the recombinant expression of mammalian cell membrane-bound human CCN1 or a CCN1 domain thereof in mammalian cells, comprising transforming a mammalian host cell with a vector encoding CCN1 or a CCN1 domain thereof C-terminally fused to a mammalian cell transmembrane domain (CCN1 fusion protein), expressing said CCN1 or CCN1 domain fusion protein in said host cell, and recovering said membrane bound CCN1 or said CCN1 domain thereof. Disclosed herein is the use of such membrane bound CCN1 and domain for the generation of corresponding antibodies. Antibodies against human CCN1 are useful for the treatment of diseases.

Abstract: The present disclosure provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for MST1R, which plays an integral role in various disorders or conditions, such as cancer. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the disclosure also can be used in the diagnostics field, as well as for further investigating the role of MST1R in the progression of disorders associated with tumors. The disclosure also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

Abstract: The present invention relates to the recognition that PAR-2 receptors amplify the inflammatory response and that effectors of PAR-2 activation can thus be used to modulate the inflammatory response and thereby impart therapeutic benefit to patients. The invention is particularly directed to the use of PAR-2 effectors in the treatment of inflammation and nociception (pain) caused by inflammation, cancer and injury. The invention is particularly directed to negative effectors of PAR-2 activation, and more particularly to anti-PAR-2 antibodies that are negative effectors of PAR-2 activation.

Abstract: Disclosed herein are methods for the recombinant expression of mammalian cell membrane-bound human CCN1 or a CCN1 domain thereof in mammalian cells, comprising transforming a mammalian host cell with a vector encoding CCN1 or a CCN1 domain thereof C-terminally fused to a mammalian cell transmembrane domain (CCN1 fusion protein), expressing said CCN1 or CCN1 domain fusion protein in said host cell, and recovering said membrane bound CCN1 or said CCN1 domain thereof. Disclosed herein is the use of such membrane bound CCN1 and domain for the generation of corresponding antibodies. Antibodies against human CCN1 are useful for the treatment of diseases.

Abstract: The present invention relates to the recognition that PAR-2 receptors amplify the inflammatory response and that effectors of PAR-2 activation can thus be used to modulate the inflammatory response and thereby impart therapeutic benefit to patients. The invention is particularly directed to the use of PAR-2 effectors in the treatment of inflammation and nociception (pain) caused by inflammation, cancer and injury. The invention is particularly directed to negative effectors of PAR-2 activation, and more particularly to anti-PAR-2 antibodies that are negative effectors of PAR-2 activation.

Abstract: The present invention provides systems, methods and apparatus for automatically provisioning and managing resources in a computing utility. Its automation procedures are based on a resource model which allows resource-specific provisioning and management tasks to be encapsulated into components for reuse. These components are assembled into more complex structures and finally computing services. This invention provides a method for constructing a computing service from a set of resources given a high level specification. Once constructed, the service includes a component that provides management function, which can allow modification of its underlying set of resources.

Abstract: The present invention provides a system, method, and computer program product to accelerate provisioning by dynamically creating dynamic free pools (DFPs) of pre-provisioned resources that are provisioned in advance, and are ready and free for use. A DFP construct for a resource, and its associated dynamic free pool manager are generated dynamically from a formal description of an aggregated resource structure (e.g. in the form of an XML schema). The present invention also provides a system, method, and computer program product to improve the delivery time of SEs based on the DFP constructs. The methods are extended to deal with special conditions such as contention over resources, or critical delivery time.

Abstract: Methods, apparatus and systems for controlling allocation and de-allocation of resources in a computing utility system, and evaluating resource assignments. Resources are dynamically allocated to customers of the computing utility through computing environments in such a way that a given objective is satisfied. Assignment of resources to environments is affected by relationships between computing environments which enable resource sharing, and constraints regarding assignment of resources to environment which limit resource sharing. The invention may be used over all of the environments in the utility or a selectable subset.

Abstract: The present invention relates to the field of networked computer and refers to a method and respective system for providing on-demand services via an electronic network from a service provider (SP) to a client requesting a service. A plurality of third-party service providers (TPSP) are involved for providing one or more on-demand services (called TPSP service) as a possible contribution to the client-requested service.

Abstract: This disclosure relates to a system, method, computer program product, and data signal for providing local marketers with an affordable, efficient, media-related service for planning and executing a marketing communications campaign using a computer-implemented system. The system and method provides the advantages typically available only to larger purchasers without having to maintain the advertising budgets of such large purchasers. The system allows the user to input preferences about the media/communications campaign into interactive worksheets. The preferences are used by a set of intelligent decision rules to produce prototype plans which present a week-by-week schedule of media purchasing as well as an allocation to various media/communications classifications. The system also allows the purchaser to vary the preferences and see the effects of the variations on the prototype plans.